Watson To Acquire Schein: Generic Business Projected At $800 Mil. In 2001
Executive Summary
Watson expects its generic drug business to top $800 mil. in revenues during 2001 after it completes the proposed acquisition of Schein.
You may also be interested in...
Watson Moves Reps To Women's, General Divisions For Branded Launches
Watson Pharmaceuticals is shifting sales reps from its dermatology division to support product launches in its general products and women's health divisions.
Watson Moves Reps To Women's, General Divisions For Branded Launches
Watson Pharmaceuticals is shifting sales reps from its dermatology division to support product launches in its general products and women's health divisions.
Watson
Investment banking firm CIBC World Markets is retained to assist in the evaluation of possible alternatives, including possible divestiture, for its two sterile injectable manufacturing facilities in Phoenix, Ariz. and Cherry Hill, N.J. Watson acquired the facilities through its recent acquisition of Schein, completed Aug. 28 (1"The Pink Sheet" May 29, p. 27). Watson said it will continue to market the injectable products INFeD and Ferrlecit. Although INFeD is manufactured at the Phoenix facility, Watson will consider a contract manufacturing arrangement for the product. Watson also names former Schein Senior VP-Quality Donald Britt as Senior VP-corporate quality assurance